Commodore Capital LP Purchases New Holdings in Replimune Group, Inc. $REPL

Commodore Capital LP acquired a new stake in Replimune Group, Inc. (NASDAQ:REPL) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 1,425,000 shares of the company’s stock, valued at approximately $13,851,000. Replimune Group comprises about 0.9% of Commodore Capital LP’s holdings, making the stock its 27th largest position.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Readystate Asset Management LP boosted its position in shares of Replimune Group by 1,296.2% during the 3rd quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock worth $10,982,000 after purchasing an additional 2,433,292 shares in the last quarter. Braidwell LP grew its holdings in shares of Replimune Group by 550.3% in the 3rd quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock worth $11,523,000 after acquiring an additional 2,327,205 shares during the period. Balyasny Asset Management L.P. increased its stake in Replimune Group by 507.4% in the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after purchasing an additional 2,195,448 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in Replimune Group during the fourth quarter worth $17,568,000. Finally, Erste Asset Management GmbH boosted its position in Replimune Group by 13,597.5% during the third quarter. Erste Asset Management GmbH now owns 1,630,000 shares of the company’s stock worth $7,074,000 after purchasing an additional 1,618,100 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Stock Performance

Replimune Group stock opened at $10.00 on Thursday. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $825.70 million, a P/E ratio of -2.91 and a beta of 0.91. The stock has a fifty day moving average price of $5.30 and a 200 day moving average price of $7.25. Replimune Group, Inc. has a 52 week low of $1.50 and a 52 week high of $13.24.

Insider Transactions at Replimune Group

In related news, insider Christopher Sarchi sold 12,000 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the sale, the insider directly owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. This represents a 6.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Wall Street Zen upgraded shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 23rd. Leerink Partners reissued a “market perform” rating and set a $2.00 price objective (down from $11.00) on shares of Replimune Group in a research note on Monday, April 13th. Cantor Fitzgerald downgraded Replimune Group from an “overweight” rating to a “hold” rating in a research report on Monday, April 13th. Piper Sandler downgraded Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price target for the company. in a research report on Friday, April 10th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $2.00 price objective (down from $13.00) on shares of Replimune Group in a research report on Monday, April 13th. Seven investment analysts have rated the stock with a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average price target of $4.88.

Replimune Group Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.